论文部分内容阅读
为明确经热处理的因子Ⅸ复合物浓缩剂(其对于病毒传染的潜在危险比未经热处理的低)治疗有抗因子Ⅷ抗体血友病甲患者的效果与未经热处理的因子Ⅸ复合物浓缩剂是否一致,作者回顾性地分析了10例不加选择的有抑制物患者的家庭治疗记录。该10例来自2个血友病中心,例1-9为有抑制物的血友病甲,例10为获得性抗因子Ⅷ抗体伴严重出血倾向。分析内容为1983年1月1日-1985年7月31日的全部出血发作。所应用的制剂,未经热处理的为NHT-Konyne,经热处理的为Konyne-HT。应用目的均是为了处理关节出血。由于1984年后NHT-Konyne被淘汰,因此本文采用回顾性自身对比。所用剂量为
Treatment of patients with anti-factor Ⅷ antibody hemophilia A for the purpose of clarifying heat-treated factor IX complex concentrates (which pose a lower risk of viral infection than non-heat-treated subjects) and of non-heat treated factor IX complex concentrates Is consistent, the authors retrospectively analyzed 10 cases of home treatment records of patients with an inhibitor of choice. The 10 cases were from two hemophilia centers, cases 1-9 were inhibitors of haemophilia A, and case 10 was acquired anti-factor Ⅷ antibody with severe bleeding tendency. Analysis of the contents of January 1, 1983 - July 31, 1985 all the bleeding episodes. The formulation used was NHT-Konyne without heat treatment and Konyne-HT with heat treatment. The purpose of the application is to treat joint bleeding. Because NHT-Konyne was eliminated after 1984, this article uses a retrospective self-comparison. The dose used is